Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2

Paniagua-Herranz, Lucía; Moreno, Irene*; Nieto-Jiménez, Cristina; Garcia-Lorenzo, Esther; Díaz-Tejeiro, Cristina; Sanvicente, Adrián; Doger, Bernard; Pedregal, Manuel; Ramón, Jorge; Bartolomé, Jorge; Manzano, Arancha; Gyorffy, Balázs [Győrffy, Balázs (Onkológia), szerző] Biofizikai Intézet (PTE / ÁOK); Onkológiai Biomarker Kutatócsoport (Lendület) (HRN TTK / MÉI); Bioinformatika Tanszék (SE / AOK / I); Gutierrez-Uzquiza, Álvaro; Pérez Segura, Pedro; Calvo, Emiliano; Moreno, Víctor; Ocana, Alberto ✉

Angol nyelvű Szakcikk (Folyóiratcikk) Tudományos
Megjelent: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 25 (4) Paper: 2222 , 14 p. 2024
  • SJR Scopus - Inorganic Chemistry: D1
Azonosítók
The identification of surfaceome proteins is a main goal in cancer research to design antibody-based therapeutic strategies. T cell engagers based on KLK2, a kallikrein specifically expressed in prostate cancer (PRAD), are currently in early clinical development. Using genomic information from different sources, we evaluated the immune microenvironment and genomic profile of prostate tumors with high expression of KLK2. KLK2 was specifically expressed in PRAD but it was not significant associated with Gleason score. Additionally, KLK2 expression did not associate with the presence of any immune cell population and T cell activating markers. A mild correlation between the high expression of KLK2 and the deletion of TMPRSS2 was identified. KLK2 expression associated with high levels of surface proteins linked with a detrimental response to immune checkpoint inhibitors (ICIs) including CHRNA2, FAM174B, OR51E2, TSPAN1, PTPRN2, and the non-surface protein TRPM4. However, no association of these genes with an outcome in PRAD was observed. Finally, the expression of these genes in PRAD did not associate with an outcome in PRAD and any immune populations. We describe the immunologic microenvironment on PRAD tumors with a high expression of KLK2, including a gene signature linked with an inert immune microenvironment, that predicts the response to ICIs in other tumor types. Strategies targeting KLK2 with T cell engagers or antibody-drug conjugates will define whether T cell mobilization or antigen release and stimulation of immune cell death are sufficient effects to induce clinical activity.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2024-11-03 06:55